Company Filing History:
Years Active: 2019-2021
Title: The Innovative Journey of Tim Schnyder
Introduction: Tim Schnyder, a prolific inventor based in Igersheim, Germany, has made significant contributions to the field of biotechnology. With a total of nine patents to his name, he is recognized for his innovative work, particularly in the area of receptor agonist proteins and therapeutic antibodies.
Latest Patents: Among his latest patents are the "Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins." This invention provides specific GITR receptor agonist proteins, as well as nucleic acids encoding them, aimed at treating subjects with GITRL-associated diseases or disorders. These proteins consist of three soluble GITRL domains and an Fc fragment, ensuring they are substantially non-aggregating and suitable for various therapeutic, diagnostic, and research applications. Another noteworthy patent is the "Monoclonal anti-CD95L (cluster of differentiation 95 ligand) antibody," which focuses on a specific CD95L antibody for the diagnosis and treatment of diseases associated with CD95L-induced signaling, including cancer.
Career Highlights: Tim Schnyder is currently associated with Apogenix AG, a company known for its cutting-edge research and development in immuno-oncology. His role at Apogenix AG has allowed him to advance his research in receptor technologies and their potential therapeutic uses.
Collaborations: Throughout his career, Schnyder has collaborated with notable colleagues in the industry, including Christian Gieffers and Oliver Hill. Their teamwork has contributed to several innovations in the field, bolstering the impact of their research on cancer treatment.
Conclusion: Tim Schnyder's journey as an inventor exemplifies the spirit of innovation in biotechnology. His latest patents illustrate the potential of his work to advance treatment options for serious diseases, reaffirming his status as a leader in his field. With ongoing collaborations and a strong commitment to research, Schnyder continues to influence the future of therapeutic solutions in medicine.